Botulinum toxin type B for treatment of spasmodic dysphonia: A case report

Robert Thayer Sataloff, Yolanda D. Heman-Ackah, Lance L. Simpson, Jong Beak Park, Amy Zwislewski, Caren Sokolow, Steven Mandel

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.

Original languageEnglish (US)
Pages (from-to)422-424
Number of pages3
JournalJournal of Voice
Issue number3
StatePublished - 2002
Externally publishedYes


  • Botulinum toxin
  • Botulinum toxin B
  • Laryngeal dystonia
  • Spasmodic dysphonia

ASJC Scopus subject areas

  • Speech and Hearing
  • LPN and LVN
  • Otorhinolaryngology


Dive into the research topics of 'Botulinum toxin type B for treatment of spasmodic dysphonia: A case report'. Together they form a unique fingerprint.

Cite this